Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4286223 | PMC |
| http://dx.doi.org/10.11604/pamj.2014.19.11.2071 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Triple immunostaining demonstrates the possible existence of segregated-nucleus-containing atypical monocytes in human primary myelofibrosis bone marrow: a case report.
J Med Case Rep
October 2024
Department of Diagnostic Pathology, Tokyo Women's Medical University Adachi Medical Center, 4-33-1, Kohoku, Adachi-ku, 123-8558, Tokyo, Japan.
Article Synopsis
- Segregated-nucleus-containing atypical monocytes have been identified in mice and are believed to induce fibrosis in drug-injured lungs, with a human counterpart potentially existing in primary myelofibrosis.
- A 74-year-old male patient with primary myelofibrosis had anemia and elevated lactate dehydrogenase, and his bone marrow showed histological features consistent with the disease.
- Immunohistochemical analysis revealed the presence of some CD16MSR1CEACAM1 cells in the patient's bone marrow, suggesting a possible connection to murine atypical monocyte characteristics.
The History of Macrophage Activation Syndrome in Autoimmune Diseases.
Adv Exp Med Biol
August 2024
Hospital for Sick Children (SickKids), University of Toronto, Toronto, ON, Canada.
Article Synopsis
- In 1979, hemophagocytic lymphohistiocytosis (HLH) was recognized as a non-cancer disease related to certain immune cells called histiocytes.
- There are two main types of HLH: familial (which runs in families) and secondary (which happens because of other diseases like autoimmune disorders).
- Macrophage activation syndrome (MAS) is a type of secondary HLH that occurs with autoimmune diseases and has unique signs and treatments, especially in cases like systemic juvenile idiopathic arthritis (sJIA).
From palliative care to a definite cure: a presentation of severe Whipple disease.
Gastrointest Endosc
September 2024
Department of Gastroenterology, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisboa, Portugal.
Tumor cell-induced platelet aggregation accelerates hematogenous metastasis of malignant melanoma by triggering macrophage recruitment.
J Exp Clin Cancer Res
October 2023
Department of Oncology, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing, China.
Background: Tumor cell-induced platelet aggregation (TCIPA) is not only a recognized mechanism for paraneoplastic thrombocytosis but also a potential breakthrough alternative for a low response to immune checkpoint inhibitors (ICIs) in hematogenous metastasis of malignant melanoma (MM). However, there is no TCIPA-specific model for further investigation of the relationship among TCIPA, the tumor immune microenvironment (TIME), and metastasis.
Methods: We developed a TCIPA metastatic melanoma model with advanced hematogenous metastasis and enhanced TCIPA characteristics.
Clinical and laboratory features associated with macrophage activation syndrome in Still's disease: data from the international AIDA Network Still's Disease Registry.
Intern Emerg Med
November 2023
Department of Medical Sciences, Surgery and Neurosciences, Research Center of Systemic Autoinflammatory Diseases, Behçet's Disease Clinic and Rheumatology-Ophthalmology Collaborative Uveitis Center, University of Siena, Siena, Italy.
Article Synopsis
- The study focuses on patients with Still's disease to identify clinical and laboratory signs associated with macrophage activation syndrome (MAS), a serious complication.
- Out of 414 patients examined, 39 (9.4%) developed MAS, with several significant variables like liver involvement and high ferritin levels linked to its occurrence.
- Multivariate analysis revealed that having hepatomegaly and monoarthritis were directly associated with MAS, while factors like a normal platelet count were protective against its development.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!